**Supplementary Materials**

Supplemental Table 1: Histopathological types of nephrotic syndrome pattern post hematopoietic stem cell transplant.

Supplemental Table 2: Treatment of renal disease with or without immunosuppressants.

Supplemental Table 3: Associated ‘extra-renal GvHD’

Supplemental Table 4: Comparison of previous studies of nephrotic Syndrome post-hematopoietic stem Cell transplant with current study.

|  |
| --- |
| **Supplemental Table 1:** **Histopathological types of nephrotic syndrome pattern post hematopoietic stem cell transplant.** |
| **Parameter** | **Membranous Nephropathy****(N=4)** | **Minimal change Disease****(N=3)** | ***p* value** |
| **Baseline characteristics (N=7)** |
| **Gender** Males (n, %) Females (n, %) | 1 (25)3 (75) | 2 (66.7)1 (33.3) | 0.486 |
| Age (years, mean ± SD) | 30.2 ± 19.6 | 25.7 ± 8.1 | 0.694 |
| **Stem cell source** (n, %) Bone marrow transplant Peripheral blood stem cell transplant | 04 (100) | 03 (100) |  |
| **Conditioning regimen** (n, %) Non-myeloablative  Reduced intensity Myeloablative | 1 (25)1 (25)2 (50) | 2 (66.7)01 (33.3) | 0.459 |
| Total body irradiation (n, %) | 2 (50) | 1 (33.3) | 0.659 |
| **GvHD prophylaxis** (n, %) Cyclosporine Post-transplant cyclophosphamide Cyclosporine + min-methotrexate Post-transplant cyclophosphamide + mycophenolate + tacrolimus | 004 (100)0 | 002 (66.7)1 (33.3) | 0.429 |
| Donor chimerism [%, median (Range)] | 100 (90-100) | 100 (100) | 0.386 |
| **Extra-renal GvHD** (n, %)Type of extra-renal GvHD (n, %) Acute GvHD Chronic GvHDSite of chronic GvHD (n, %) Lichen planus Mucosa Liver Lung Multiple sitesStage of chronic GvHD (n, %) Mild Moderate SevereTime to diagnosis from HSCT [months (range)] Chronic extra-renal GvHD Nephrotic syndrome pattern post HSCT | 2 (50)02 (50)1 (50)1 (50)1 (50)1 (50)1 (50)1 (50)01 (50)4 (3-5)18.5 (13-69) | 1 (33.3)01 (33.3)1 (100)1 (100)001 (100)01 (100)0512 (7-77) | 0.6590.6590.4800.857 |
| Time to diagnosis after withdrawal of GvHD prophylaxis [months, median (range)] Extra-renal GvHD Nephrotic syndrome post HSCT | 09.5 (0-34) | 24 (1-61) | 0.724 |
| New onset hypertension (n, %) | 1 (25) | 1 (33.3) | 0.809 |
| Hemoglobin (g/dL, mean ± SD) | 11.8 ± 2.5 | 15.3 ± 2.5 | 0.132 |
| Serum creatinine at biopsy [mg/dL, median (range)] | 0.5 (0.3-3.9) | 1 (0.5-1.4) | 0.480 |
| eGFR CKD-EPI at biopsy [ml/min/1.73 m², median (range)] | 137 (12.1-160) | 97.8 (73.1-151.4) | 0.480 |
| 24-hour urine protein [g/day, median (range)] | 7.1 (3.6-11.4) | 7.5 (1.5-12) | >0.050 |
| Serum albumin (g/dL, mean ± SD) | 2.9 ± 0.5 | 2.9 ± 1.8 | 0.994 |
| Hematuria (n, %) Visible hematuria Non-visible hematuria | 02 (50) | 01 (33.3) | 0.659 |
| Leucocyturia (n, %) | 2 (50) | 1 (33.3) | 0.659 |
| Casts (n, %) | 1 (25) | 1 (33.3) | 0.809 |
| **Kidney biopsy (N=7)** |
| Time to renal biopsy from HSCT [months, median (range)] | 18.5 (13-69) | 12 (7-77) | 0.480 |
| Globally sclerotic glomeruli [%, median (range)] | 0 (0-52) | 0 (0-28) | >0.05 |
| **Glomerular lesions** (n, %) Mesangiolysis (focal, diffuse) | 1, 0 (25, 0) | 1, 0 (33.3, 0) | 0.809 |
| **Tubular lesions** (n, %) Acute tubular injury Tubulitis (t1, t2, t3) | 1 (25)0 | 0, 0, 0 (0, 0, 0)0 | 0.350 |
| **Interstitial lesions** (n, %) Peri-tubular capillaritis (ptc1, ptc2, pc3) Interstitial inflammation (i1, i2, i3) IFTA (ci1, ci2, ci3) Inflammation in area of IFTA (i-IFTA1, i-IFTA-2, iIFTA-3) | 01, 0, 0 (25, 0, 0)0, 0, 1 (0, 0, 25)1, 0, 0 (25. 0. 0) | 0000 | 0.3500.3500.350 |
| **Arteriolar lesions** (n, %) Arteriosclerosis (cv1, cv2, cv3)) Arteriolar hyalinosis (ah1, ah2, ah3) | 0, 1, 0 (0, 25, 0)1, 0, 0 (25, 0, 0) | 0, 0, 00, 0, 0  | 0.3500.350 |
| **Immunohistochemistry** (n, %) Positive glomerular C4d Staining \* Positive PLA2R staining\* | 3 (100)1 (25) | 0 | 0.025 |
| **Immunofluorescence** (n, %) IgG IgM IgA C3 | 4 (100)02 (50)4 (100) | 0000 | 0.2570.4290.047 |
| **Electron Microscopy** (n, %) \***Foot process effacement** Near total Segmental (<50%)**Deposits** Sub-epithelial deposits only Sub-epithelial + sub endothelial + mesangialTubuloreticular inclusions Superimposed TMA | 04 (100)3 (75)1 (25)1 (25)1 (25) | 2(66.7)1 (33.3)00000 | 0.400 |
| **Treatment characteristics (N=7)** |
| Renin angiotensin system inhibitors (n, %) | 1 (25) | 2 (66.7) | 0.486 |
| **Immunosuppression** (n, %) Steroid alone Steroid plus add-on immunosuppressant Plasmapheresis | 1 (25)2 (50)0 | 2 (66.7)00 | 0.657 |
| **Outcome at last follow up (N=7)** |
| >3 months follow up (n, %) | 4 (100) | 3 (100) |  |
| Follow-up [months, median (range)] | 14 (5-37) | 22 (19-81) | 0.157 |
| **Renal outcomes** (n, %) Remission Stabilization Worsening Kidney failure | 3 (75)001 (25) | 2 (66.7)1 (33.3)00 | 0.472 |
| **Proteinuria outcomes** (n, %) \* Complete remission Partial remission No remission | 2 (50)1 (25)1 (25) | 2 (100)00 | 0.472 |
| Time to complete remission of proteinuria [median (range)] | 0.5 (0-1) | 4 (1-7) | 0.221 |
| Post-transplant infections (n, %) | 2 (50) | 2 (66.7) | 0.659 |
| Death (n, %) | 1 (25) | 0 | 0.350 |
| CKD-EPI, Chronic Kidney Disease-Epidemiology; eGFR, Estimated glomerular filtration rate; GvHD, Graft versus host disease; HSCT, Hematopoietic stem cell transplant; IFTA, Interstitial fibrosis and tubular atrophy; PLA2R, Phospholipase 2 Receptor; SD, Standard deviation. \* N equals 5 (C4d staining), 4 (PLA2R staining), 6 (Proteinuria outcomes), 5 (Electron microscopy) |

|  |
| --- |
| **Supplemental Table 2:** **Treatment of renal disease with and without immunosuppressants.** |
| **Parameter** | **Immunosuppression Yes****(N=12)** | **Immunosuppression No****(N=7)** | ***p* value** |
| **Baseline characteristics (N=19)** |
| **Gender (n, %)** Males  Females  | 7 (58.3)5 (41.7) | 6 (85.7)1 (14.3) | 0.333 |
| Age (years, mean ± SD) | 26.7 ± 12.4 | 37.8 ± 14.8 | 0.095 |
| **Stem cell source** (n, %) Bone marrow transplant Peripheral blood stem cell transplant | 2 (16.7)10 (83.3) | 07 (100) | 0.509 |
| **Conditioning regimen** (n, %) Non-myeloablative  Reduced intensity Myeloablative | 7 (71.4)1 (8.3)4 (33.3) | 5 (71.4)1 (14.3)1 (14.3) | 0.804 |
| Total body irradiation (n, %) | 8 (66.7) | 2 (28.6) | 0.170 |
| **GvHD prophylaxis** (n, %) Cyclosporine Post-transplant cyclophosphamide Cyclosporine + mini-methotrexate Post-transplant cyclophosphamide + mycophenolate + tacrolimus | 1 (8.3)3 (25)7 (58.3)1 (8.3) | 01 (14.3)6 (85.7)0 | 0.847 |
| Donor chimerism [%, median (range)] | 100 (90-100) | 100 (100) | 0.445 |
| **Extra-renal GvHD** (n, %)Type of extra-renal GvHD (n, %) Acute GvHD Chronic GvHDTime to diagnosis from HSCT [months (range)] Acute extra-renal GvHD Chronic extra-renal GvHD TMA or NS post-HSCTTime to diagnosis after withdrawal of GvHD prophylaxis [months, median (range)] Extra-renal GvHD TMA or NS post-HSCT | 7 (58.3)3 (25)6 (50)1 (1)4 (1-9)12.5 (1-21)1 (0-11)2 (0-25) | 4 (57.1)2 (28.6)3 (42.8)1 (0-8)5 (3-5)17 (8-77)0.5 (0-1)22 (2-61) | 0.9600.978>0.050.7840.0560.5940.038 |
| New onset hypertension (n, %) | 3 (25) | 3 (42.9) | 0.216 |
| Hemoglobin (g/dL, mean ± SD) | 10.9 ± 2.9 | 11.6 ± 3.1 | 0.599 |
| Serum creatinine at biopsy [mg/dL, median (IQR)] | 1.8 (0.5-2.1) | 2.8 (2.1-5.5) | 0.018 |
| eGFR CKD-EPI at biopsy [ml/min/1.73 m², median (IQR)] | 55.5 (36-143.1) | 25.5 (11.8-30.9) | 0.011 |
| 24-hour urine protein [g/day, median (IQR)] | 1.5 (0.4-7.5) | 0.7 (0.5-4) | 0.580 |
| Serum albumin (g/dL, mean ± SD) | 3.2 ± 0.9 | 3.9 ± 0.7 | 0.087 |
| Hematuria (n, %) Visible hematuria Non-visible hematuria | 03 (25) | 00 | 0.263 |
| Leucocyturia (n, %) | 4 (33.3) | 0 | 0.245 |
| Casts (n, %) | 3 (25) | 2 (28.6) | 0.865 |
| **Kidney Biopsy (N=19)** |
| Time to biopsy from HSCT [months, median (range)] | 12.5 (1-21) | 17 (8-77) | 0.056 |
| **Pattern of renal disease** (n, %) TMA Nephrotic Syndrome | 7 (58.3)5 (41.7) | 5 (71.4)2 (28.6) | 0.656 |
| Globally sclerotic glomeruli [%, median (IQR)] | 0 (0-18.5) | 9 (0-28) | 0.157 |
| **Glomerular lesions** (n, %) Mesangiolysis (focal, diffuse) | 7, 1 (58.3, 14.3) | 4, 1 (57.1, 14.3) | 0.981 |
| **Tubular lesions** (n, %) Acute tubular injury Tubulitis (t1, t2, t3) | 8 (66.7)0 | 6 (85.7)2 (28.6) | 0.7940.123 |
| **Interstitial lesions** (n, %) Peri-tubular capillaritis (ptc1, ptc2, pc3) Interstitial inflammation (i1, i2, i3) IFTA (ci1, ci2, ci3) Inflammation in area of IFTA (i-IFTA1, i-IFTA-2, iIFTA-3) | 01, 2, 0 (8.3, 16.7, 0)3, 0, 0 (25, 0, 0)2, 1, 0 (16.7. 8.3. 0) | 01, 1, 1 (14.3, 14.3, 14.3)2, 0, 1 (28.6, 0, 14.3)0, 2, 0 (0, 28.6, 0) | 0.7450.5740.583 |
| **Arteriolar lesions** (n, %) Arteriosclerosis (cv1, cv2, cv3)) Arteriolar hyalinosis (ah1, ah2, ah3) | 1, 2, 0 (8.3, 16.7, 0)2, 2, 0 (16.7, 16.7, 0) | 1, 2, 0 (14.3, 28.6, 0)3, 0, 0 (42.9, 0, 0) | 0.7960.489 |
| **Immunohistochemistry** (n, %) \* Positive C4d staining  | 4 (44.4) | 3 (60) | 0.577 |
| **Immunofluorescence** (n, %) IgG IgM IgA C3 | 3 (25)02 (16.7)3 (25) | 1 (14.3)2 (28.6)1 (14.3)1 (14.3) | 0.7180.1230.8910.581 |
| **Treatment characteristics (N=19)** |
| Renin angiotensin system inhibitors (n, %) | 5 (41.7) | 2 (28.6) | 0.486 |
| Immunosuppression (n, %) Steroid alone Steroid plus add-on immunosuppressant Plasmapheresis | 5 (41.7)7 (58.3)1 (8.3) | 000 | 0.433 |
| **Outcome at last follow-up (N=17)** |
| >3 months follow-up (n, %) | 11 (91.7) | 6 (85.7) |  |
| Follow-up [months, median (range)] | 37 (5-162) | 14 (7-22) | 0.078 |
| **Renal outcomes** (n, %) Remission Stabilization Worsening Kidney failure | 8 (72.7)1 (9.1)02 (18.2) | 1 (16.7)1 (16.7)2 (33.3)2 (33.3) | 0.044 |
| **Proteinuria outcomes** (n, %) \* Complete remission Partial remission No remission | 4 (50)2 (25)2 (25) | 2 (50)02 (50) | 0.758 |
| Post-transplant infections (n, %) | 7 (63.6) | 5 (83.3) | 0.600 |
| Death (n, %) | 2 (18.2) | 3 (50) | 0.280 |
| CKD-EPI, Chronic Kidney Disease-Epidemiology; eGFR, Estimated Glomerular Filtration Rate; GvHD, Graft Versus Host Disease; IFTA, Interstitial fibrosis and tubular atrophy; IQR, Inter-quartile range; SD, Standard deviation. \* n equal 14 (C4d staining), 12 (proteinuria outcomes) |

|  |
| --- |
| **Supplemental Table 3: ‘Associated extra-renal GvHD****’**  |
| **Parameter** | **Associated extra-renal GVHD Yes****(N=11)** |  **Associated extra-renal GVHD No****(N=8)** | ***p* value** |
| **Baseline characteristics (N=19)** |
| **Gender (n, %)** Males  Females  | 10 (90.9)1 (9.1) | 3 (37.5)5 (62.5) | 0.041 |
| Age (years, mean ± SD) | 29.3 ± 15.6 | 32.9 ± 12.5 | 0.597 |
| **Stem cell source** (n, %) Bone marrow transplant Peripheral blood stem cell transplant | 2 (18.2)9 (81.8) | 08 (100) | 0.485 |
| **Conditioning regimen** (n, %) Non-myeloablative  Reduced intensity Myeloablative | 5 (45.5)2 (18.2)4 (36.4) | 7 (87.5)01 (12.5) | 0.245 |
| Total body irradiation (n, %) | 7 (63.6) | 3 (37.5) | 0.370 |
| **GvHD prophylaxis** (n, %) Cyclosporine Post-transplant cyclophosphamide Cyclosporine + mini-methotrexate Post-transplant cyclophosphamide + mycophenolate  tacrolimus | 1 (9.1)2 (18.2)7 (63.6)1 (9.1) | 02 (25)6 (75)0 | 0.649 |
| Donor chimerism [%, median (IQR)] | 100 (100-100) | 100 (100-100) | 0.394 |
| **Type of extra-renal GvHD** (n, %) Acute GvHD Chronic GvHD | 5 (45.4)9 (81.8) | 00 |  |
| **Time to diagnosis after withdrawal of GvHD prophylaxis** [months, median (IQR)] Extra-renal GvHD TMA or NS post-HSCT | 0.5 (0-3.5)4 (2-25) | 4.5 (1.25-15) | 0.868 |
| **Hypertension** (n, %) New onset hypertension Long standing hypertension | 3 (27.3)1 (9.1) | 3 (37.5)0 | 0.644 |
| Serum creatinine at biopsy [mg/dl, median (IQR)] | 2.3 (1.4-3.1) | 1.4 (0.6-2.1) | 0.283 |
| eGFR CKD-EPI at biopsy [ml/min/1.73 m², median (IQR)] | 35.5 (24.6-81.9) | 73.1 (25.5-118.3) | 0.409 |
| 24-hour urine protein [g/day, median (IQR)] | 1.1 (0.2-4.6) | 1.5 (0.6-10.5) | 0.526 |
| Serum albumin (g/dL, mean ± SD) | 3.9 (2.8-4) | 3.6 (2.7-4.1) | 0.967 |
| **Kidney biopsy (n=19)** |
| **Pattern of renal disease** (n, %) Thrombotic microangiopathy Nephrotic syndrome | 8 (72.7)3 (27.3) | 4 (50)4 (50) | 0.377 |
| Time to renal biopsy from HSCT [months, median (IQR)] | 15 (9-17) | 12.5 (9-19.5) | 0.709 |
| Globally sclerotic glomeruli [%, median (IQR)] | 0 (0-17) | 0 (0-10.5) | 0.811 |
| **Glomerular lesions** (n, %) GBM double contouring (cg1, cg2, cg3) Mesangiolysis (Focal, diffuse) | 3 (27.3)6, 2 (54.5, 18.2) | 05, 1 (62.5, 12.5) | 0.2280.926 |
| **Tubular lesions** (n, %) Acute tubular injury Tubulitis (t1, t2, t3) | 9 (81.8)1 (9.1) | 5 (62.5)1 (12.5) | 0.8020.678 |
| **Interstitial lesions** (n, %) Interstitial inflammation (>25%) IFTA (>25%) | 2 (18.2)1 (9.1) | 2 (25)0 | 0.7190.381 |
| **Arteriolar lesions** (n, %) Arteriosclerosis (>25%) Arteriolar hyalinosis (>25%) | 3 (27.3)2 (18.2) | 1 (12.5)0 | 0.6030.485 |
| **Immunofluorescence** (n, %) Positive C3 staining Positive IgG staining Positive IgM staining Positive IgA staining | 1 (9.1)1 (9.1)00 | 3 (37.5)3 (37.5)00 | 0.2620.347 |
| **Immunohistochemistry** (n, %) \* C4d staining | 1 (14.3) | 3 (42.9) | 0.559 |
| **Treatment characteristics (N=19)** |
| Renin angiotensin system inhibitors (n, %) | 3 (27.3) | 4 (50) | 0.377 |
| **Immunosuppression** (n, %) Steroid alone Steroid plus add-on immunosuppressant Plasmapheresis | 2 (18.2)5 (45.5)1 (9.1) | 3 (37.5)2 (25)0 | 0.8380.8380.381 |
| **Outcomes at last follow-up (n=17)** |
| >3 months follow-up (n, %) | 10 (90.9) | 7 (87.5) | 0.811 |
| Follow-up duration [months, median (IQR)] | 20 (11.25-53) | 22 (12-47) | 0.961 |
| **Renal outcomes** (n, %) Remission Stabilization Worsening Kidney failure | 4 (40)1 (10)1 (10)4 (40) | 5 (71.4)1 (14.3)1 (14.3)0  | 0.327 |
| **Proteinuria outcomes** (n, %) \* Complete remission Partial remission No remission | 4 (50)04 (50) | 2 (50)2 (50)0 | **0**.050 |
| Post-transplant infections (n, %) | 10 (90.9) | 4 (50) | 0.046 |
| Death (n, %) | 6 (60) | 0 | 0.023 |
| CKD-EPI, Chronic Kidney Disease-Epidemiology; eGFR, Estimated glomerular filtration rate; GvHD, Graft versus Host Disease; GBM, Glomerular basement membrane; IFTA, Interstitial fibrosis and tubular atrophy; IQR, Inter quartile range; SD, Standard deviation. \*n equals 14 (C4d staining) and 12 (Proteinuria outcomes) |

|  |
| --- |
| **Supplemental table 4: Comparison of previous studies of nephrotic syndrome post-hematopoietic stem cell transplant with current study.** |
| **Author** | **Beyar-Katz et al.****[33]** | **Niscola** **et al.****[34]** | **Hu** **et al.****[35]** | **Colombo et al.****[36]** | **Fraile** **et al.****[37]** | **Srinivasan et al.****[38]** | **Reddy** **et al.****[39]** | **Hiramatsu** **et al.****[40]** | **Huang** **et al.****[41]** | **Terrier** **et al.****[42]** | **Current study** |
| Cohort duration | 1988-2015 | Up to 2012 | - | 1992-2003 | 1995-2012 | 1997-2003 | 1994-2002 | 2000-2012 | 2006-2009 | - | 2005-2020 |
| Country | Pooled analysis | Pooled Analysis | Pooled Analysis | Italy | Spain | USA | USA | Japan | China | France | India |
| Number of patients | 116 | 69 | 95 | 6 | 6 | 7 | 9 | 5 | 5 | 5 | 7 |
| Incidence of renal GvHD (%) | - | - | - | 2.8 | 1.03 | 6.3 | 1 | 0.6 | - | - | 0.3 |
| Gender (Male: Female ratio) | 2.4:1 | 1.5:1 | 2.06:1 | 6:1 | 1:1 | 1.3:1 | 2:1 | 4:1 | 3:2 | 2:3 | 0.6:1 |
| Age [years, mean ± SD or median (range)] | 44 (18-68) | 43 (5-68) | 40 ± 16 | 47.5 ±11.8 | 45.3 ± 12 | 46 (33-59) | 54 (37-58) | 50.2 ± 9.3 | 37.8 ±15.5 | 51 ± 9.4 | 28.3 ± 14.8 |
| **Basic hematologic disease** (%) Aplastic anemia Hematological malignancies Thalassemia Myelodysplastic syndrome Others | -75.9--24.1 | -76.6--23.4 | - | 66.633.3 | -100--- | -28.6--71.4 | -66.6-11.122.2 | -80-20- | -100--- | -80-20- | 57.128.614.3 |
| **Stem cell source** (%)Bone marrow transplantPeripheral blood stem cell transplantCord blood | 20.7772.3 | - | 29610 | 16.683.30 | -100- | - | 01000 | --100 | - | - | 01000 |
| **Type of Donor** (%) Matched related donor Matched unrelated donor Haploidentical donor | 84.413- | - | - | 83.316.70 | 83.316.7- |  96.33.7 | 77.822.20 | - | 8020- | - | 85.7-14.3 |
| **Conditioning regimen** (n, %) Non-myeloablative Reduced intensity Myeloablative | -25.574.5 | - |  36 | -33.366.7 | 16.7-83.3 | 10000 | 022.277.8 | --100 | --100 | 80020 | 42.914.342.9 |
| Total body irradiation (%) | 51.9 | - | - | 16.7 | - | - | 55.5 | 80 | 20 | 40 | 42.9 |
| **GvHD prophylaxis** (%) CNI CNI + methotrexate Others |  | - | - | 100-- | 83.3-16.7 | - | -100- | - | - | 08020 | 85.714.3 |
| Time to renal biopsy from HSCT [months, median (range)] | 20.5(3-174) | 17 (3-134) | 22.9 ± 25.2 | 23 (13-43) | 33 ± 11.5 | 10.6 (3.9-40.1) | - | 18 (9-40) | 19 (10-22) | 24.4 (14-37) | 16 (7-77) |
| Hypertension at presentation (%) |  | - | - | - | - | - | 77.8 | - | - | - | 28.6 |
| Serum creatinine at biopsy [mg/dL, median (range)] | - | - | - | 0.9 (0.7-1.07) | - | 0.9 (0.5-1.2) | - | 1 (0.8-1.3 | 0.7 (0.6-0.8) | - | 0.6 (0.4-1.4) |
| eGFR CKD-EPI at biopsy [ml/min/1.73 m², median (range)] | - | - | - | - | - | - | - | 47 (45-89) | - | 57(41-78.4) | 118.3 (73.1-155.7) |
| 24-hour urine protein [g/day, median (IQR)] | 8.5 (0-35) | - | 8.4 | 6.5 (3.5-12) | 11.8 ± 9 | 16.5 (3-24) | 3.6-27 | 7.9 (5.9-13) | 4.6 (3.3-6.5) | 8.5 (7.9-16.2) | 7.5 (3.6-11.4) |
| **Histological diagnosis** (%) Minimal change disease Membranous nephropathy Focal segmental glomerulosclerosis IgA nephropathy Membranoproliferative glomerulonephritis Lupus nephritis Not biopsied | 1965.57.72.65.2-- | -100----- | 2067.4----- | 16.766.7-16.7--- | 16.766.7---16.7- | -57.2----42.8 | 11.155.5----33.3 | -80--20-- | -100----- | -100----- | 42.957.1----- |
| Renin angiotensin system inhibitors (%) | - | - | - | - | - | - | 77.8 | - | - | 100 | 42.9 |
| **Immunosuppression** (%) Steroid alone Steroid plus add-on immunosuppressant | 16.873.5 | -89.5 | - | -100 | 16.783.3 | 28.671.4 | 33.366.7 | 2060 | 2080 | -100 | 42.928.6 |
| Extra-renal GvHD (%)**Type of Extra-renal GvHD** (%) Acute GvHD Chronic GvHDTime to diagnosis after withdrawal of GvHD prophylaxis [months, Median (Range)] Extra-renal GvHD  NS post HSCT Breakthrough GVHD (%) | 87.259.675.2-6 9 (0.75-29)42.1 | -6886--- | 72---3.7 ± 6- | 10016.71004 (3.2-8.2)23 (13-43)- | 50---13 ± 9.816.7 | 57.1-57.1--57.1 | 77.822.277.811.4 (6.2-19.2)24.5 (12.8-42.6)- | 1000100--- | 100-100-4 (1-16)- | 10080100--- | 42.9042.90 (0-2)4 (0-61)15.8 |
| **Outcomes** Follow up duration [months, median (range)] Complete remission of proteinuria (%) Kidney failure (%) Death (%) | -63.519.213.7 | -5913- | 12 (1-96)70-13 | 46 (18.5-61.2)66.7016.7 | -66.7-- | 33.628.642.871.4 | -66.7-22.2 | 96 (38-144)10020- | -2000 | 17.5 (8-36)502525 | 19 (5-81)66.714.314.3 |
| CKD-EPI, Chronic Kidney Disease-Epidemiology; CNI, Calcineurin inhibitor; eGFR, Estimated glomerular filtration rate; GvHD, Graft versus Host Disease; HSCT, Hematopoietic stem cell transplant; SD, Standard deviation. |